Table 1.
Characteristics of study cohort diagnosed with cancer during the pre–COVID-19 (January 1, 2019, to January 14, 2020) and COVID-19 (January 15, 2020, to December 31, 2020) periods—Indiana, 2019-2020 (N=41,924).
| Characteristics | Pre–COVID-19 period | COVID-19 period | Total | |||||||||
|
|
Dead | Dead |
|
|||||||||
|
|
No (n=18,895), n (%) | Yes (n=2074), n (%) | No (n=19,631), n (%) | Yes (n=1324), n (%) |
|
|||||||
| Age range (years) | ||||||||||||
|
|
18-44 | 1638 (8.7) | 86 (4.2) | 1635 (8.3) | 30 (2.3) | 3389 (8.1) | ||||||
|
|
45-64 | 7005 (37.0) | 631 (30.4) | 7100 (36.2) | 366 (27.6) | 15,102 (36.0) | ||||||
|
|
≥65 | 10,252 (88.3) | 1357 (65.4) | 10,896 (55.5) | 928 (70.1) | 23,433 (55.9) | ||||||
| Race or ethnicity | ||||||||||||
|
|
White | 15,051 (79.6) | 1694 (81.7) | 15,015 (76.5) | 1107 (83.6) | 32,867 (78.4) | ||||||
|
|
Black | 1239 (6.6) | 166 (8.0) | 1173 (6.0) | 93 (7.0) | 2671 (6.4) | ||||||
|
|
Hispanic | 416 (2.2) | 28 (1.3) | 371 (1.9) | 17 (1.3) | 832 (2.0) | ||||||
|
|
Other | 2189 (11.6) | 186 (9.0) | 3072 (15.6) | 107 (8.1) | 5554 (13.2) | ||||||
| Sex | ||||||||||||
|
|
Female | 9345 (49.5) | 889 (42.9) | 9725 (49.5) | 611 (46.1) | 20,570 (49.1) | ||||||
|
|
Male | 9550 (50.5) | 1185 (57.1) | 9906 (50.5) | 713 (53.9) | 21,354 (50.9) | ||||||
| Comorbidities | ||||||||||||
|
|
0 | 13,863 (73.4) | 1095 (52.8) | 14,567 (74.2) | 699 (52.8) | 30,224 (72.1) | ||||||
|
|
1 | 3221 (17.0) | 495 (23.9) | 3313 (16.9) | 324 (24.5) | 7353 (17.5) | ||||||
|
|
≥2 | 1811 (9.6) | 484 (23.3) | 1751 (8.9) | 301 (22.7) | 4347 (10.4) | ||||||
| Cancer | ||||||||||||
|
|
Breast | 2743 (14.5) | 101 (4.9) | 2919 (14.9) | 34 (2.6) | 5797 (13.8) | ||||||
|
|
Colorectal | 1391 (7.4) | 131 (6.3) | 1438 (7.3) | 83 (6.3) | 3043 (7.3) | ||||||
|
|
Leukemia | 665 (3.5) | 95 (4.6) | 714 (3.6) | 65 (4.9) | 1539 (3.7) | ||||||
|
|
Lip, oral cavity, and pharynx | 415 (2.2) | 48 (2.3) | 466 (2.4) | 25 (1.9) | 954 (2.3) | ||||||
|
|
Lung, trachea, and bronchus | 1629 (8.6) | 431 (20.8) | 1662 (8.5) | 322 (24.3) | 4044 (9.6) | ||||||
|
|
Lymphoma | 821 (4.3) | 100 (4.8) | 859 (4.4) | 51 (3.8) | 1831 (4.4) | ||||||
|
|
Myeloma | 411 (2.2) | 46 (2.2) | 328 (1.7) | 26 (2.0) | 811 (1.9) | ||||||
|
|
Other hematological | 97 (0.5) | 7 (0.3) | 89 (0.5) | 2 (0.1) | 195 (0.5) | ||||||
|
|
Other digestive | 1033 (5.5) | 367 (17.7) | 1139 (5.8) | 225 (17.0) | 2764 (6.6) | ||||||
|
|
Prostate | 2592 (13.7) | 103 (5.0) | 2729 (13.9) | 44 (3.3) | 5468 (13.0) | ||||||
|
|
Skin (melanoma) | 2734 (14.5) | 98 (4.7) | 2511 (12.8) | 43 (3.2) | 5386 (12.8) | ||||||
|
|
Urinary tract | 1270 (6.7) | 125 (6.0) | 1399 (7.1) | 78 (5.9) | 2872 (6.8) | ||||||
|
|
Othera | 3094 (16.4) | 422 (20.3) | 3378 (17.2) | 326 (24.6) | 7220 (17.2) | ||||||
| COVID-19 positive | ||||||||||||
|
|
No | 17,545 (92.9) | 1942 (93.6) | 18,346 (93.4) | 1197 (90.4) | 39,030 (93.1) | ||||||
|
|
Yes | 1350 (7.1) | 132 (6.4) | 1285 (6.5) | 127 (9.6) | 2894 (6.9) | ||||||
| Region | ||||||||||||
|
|
Urban | 14,436 (76.4) | 1536 (74.1) | 14,222 (72.5) | 952 (71.9) | 31,146 (74.3) | ||||||
|
|
Rural | 4459 (23.6) | 538 (25.9) | 5409 (27.5) | 372 (28.1) | 10,778 (25.7) | ||||||
aIncludes cancer types such as malignant neoplasia of the bone and articular tissue, endocrine glands, central nervous system, mesothelioma and soft tissue, male reproductive organs (excluding prostate), and female reproductive organs.